Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp is experiencing strong growth in its plasma segment, with an 18.6% organic increase on a year-over-year basis excluding CSL impact, supported by gains in market share, pricing, and higher collection volumes. The company's gross margin improved by 380 basis points year over year, and the operating margin increased by 250 basis points, indicating a positive shift in operational efficiency and profitability. Additionally, Haemonetics projects free cash flow for FY26 to rise to between $170 million and $210 million, reflecting a stronger financial outlook compared to prior estimates.

Haemonetics Corporation has experienced a significant decline in plasma sales, reporting a 10.1% organic decrease to $125.4 million, contrasting with prior expectations and reflecting the struggles in its esophageal protection business that have adversely affected overall financial performance. For FY2026, the company anticipates a total reported revenue decline of 1% to 4%, while both its organic hospital growth and the previously optimistic growth range have been revised downward, indicating challenges in maintaining growth momentum. Additionally, the blood center segment, which faces increased competition, reported a notable 17.6% decline in revenue, further compounding concerns regarding the company’s overall profitability and market position.